Document is current
Any future updates will be listed below
-
Authors
Prasanna, Hari https://orcid.org/0009-0006-6396-4167
Inderjeeth, Charles A. https://orcid.org/0000-0003-0535-963X
Nossent, Johannes C. https://orcid.org/0000-0002-2833-7997
Almutairi, Khalid B. https://orcid.org/0000-0002-9246-7294
-
Funding
Funding for this research was provided by:
University of Western Australia
- License Information
-
More Information
Article History
Received: 8 July 2024
Accepted: 5 January 2025
First Online: 18 January 2025
Declarations
:
: Ethics approval was not required for this study as it involves a review of anonymised published data. The findings of our final report will be disseminated to the scientific community through publication in a peer-reviewed journal and presentation at conferences. All authors have endorsed the final version of this manuscript and take full responsibility for the integrity and accuracy of all aspects of the work.
: In compliance with the Joanna Briggs Institute guidelines for conducting a systematic review of prevalence data and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we have registered our systematic review protocol with PROSPERO. PROSPERO ID = CRD42024508438. Our protocol was also published with INPLASY and can be found at
: No amendments were made to the protocol since registration.
: Preliminary results from this study were presented as a poster with abstract at the 26th Asia-Pacific League of Associations for Rheumatology Congress (APLAR) held across 21–25 August 2024 and the American College of Rheumatology (ACR) convergence held across 14-19 November 2024. The references for these abstracts are as follows:
: Poster Abstracts Part A (2024). International Journal of Rheumatic Diseases. 27(S3):e15345. .
: Prasanna, H., Inderjeeth, C., Nossent, J., & Almutairi, K. (2024). The Global Prevalence of Interstitial Lung Disease in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis. Arthritis Rheumatol, 76(s9).
: The authors have no conflict of interest in this study. Dr. Charles Inderjeeth reports Advisory Board Membership for ILD – Boehringer Ingelheim Pty Limited and funding from Amgen, Pfizer and Sandoz outside of the submitted work. Authors Dr Nossent, Dr Almutairi and H Prasanna have no disclosures to report.
